Strategic alliance Biovian has merged with 3P Biopharmaceuticals to form 3PBIOVIAN, signaling a broader European CDMO footprint and increased capacity for end-to-end biologics manufacturing, which presents cross-sell opportunities to existing clients of both legacy brands.

Expanded capabilities The combined service suite spans microbial and mammalian expression, viral vectors, cell therapy, plasmid DNA production, and fill-finish, enabling turnkey solutions for clients pursuing biosimilars, gene therapies, and advanced therapies.

Geographic reach With manufacturing sites in Pamplona-Noáin, Spain and Turku, Finland, 3PBIOVIAN can support pre-clinical through commercial manufacturing across Europe, appealing to biotech groups seeking regional supply stability and multicountry clinical trial capabilities.

Innovation focus Recent launches and collaborations, such as the AAVion platform and a biosimilar mAb development contract, indicate a strong emphasis on scalable viral vector and biosimilar programs, offering targeted opportunities with gene therapy and oncology developers.

Growth signals Industry recognition, leadership hires in advanced therapies, and a recent partnership for intranasal vaccine production suggest an expanding commercial engine and opportunities to upsell CDMO services to vaccine and biotech innovators seeking reputable manufacturing partners.